



# Company presentation

LeadIng.



THE LINDE GROUP

June 2016

This presentation contains forward-looking statements about Linde AG (“Linde”) and their respective subsidiaries and businesses. These include, without limitation, those concerning the strategy of an integrated group, future growth potential of markets and products, profitability in specific areas, the future product portfolio, development of and competition in economies and markets of the Group.

These forward looking statements involve known and unknown risks, uncertainties and other factors, many of which are outside of Linde’s control, are difficult to predict and may cause actual results to differ significantly from any future results expressed or implied in the forward-looking statements in this presentation.

While Linde believes that the assumptions made and the expectations reflected in this presentation are reasonable, no assurance can be given that such assumptions or expectations will prove to have been correct and no guarantee of whatsoever nature is assumed in this respect. The uncertainties include, inter alia, the risk of a change in general economic conditions and government and regulatory actions. These known, unknown and uncertain factors are not exhaustive, and other factors, whether known, unknown or unpredictable, could cause the Group’s actual results or ratings to differ materially from those assumed hereinafter. Linde undertakes no obligation to update or revise the forward-looking statements in this presentation whether as a result of new information, future events or otherwise.

## 1. Operational Performance

## 2. Strategic Focus

- Resilient Gases Business Model
- Growth
- Returns

## 3. Outlook

# Performance Q1 2016

## Highlights



[EUR]		Q1 2015	Q1 2016	yoy [%]	yoy [%] adj.for FX
Revenue	[m]	4,398	4,262	-3.1	-0.3
Operating profit	[m]	1,010	991	-1.9	+0.6
Operating margin	[%]	23.0	23.3	+30bps	
Operating cash flow	[m]	740	883	+19.3	
EPS reported		1.62	1.65	+1.9	


- Revenue development impacted by currency headwinds and expected lower Engineering contribution
- Impact from first price adjustment from Competitive Bidding more than compensated by American HomePatient acquisition
- Strong operating cash flow

Please see definitions of key financial figures in the appendix

# Group | Revenue and operating profit by division


## Revenue development impacted by currency headwinds

### Revenue [EUR m]



■ Gases ■ Engineering ■ Other/Cons.

### Operating profit [EUR m]



■ Gases ■ Engineering ■ Other/Cons.

#### Gases

Revenue impacted by FX and supported by Healthcare acquisition

#### Engineering

Revenue development in line with expectations

#### Gases

Stable operating profit despite negative FX impact


#### Engineering

Margin in line with medium-term guidance of around 8 percent

# Gases Division | Revenue by product areas

## Positive growth development in Q1 2016

Comparable growth\*  
[EUR m]



\*Excludes currency and natural gas price effects

### Comments / Additional effects



#### Healthcare

Strong growth supported by American HomePatient, +3.3% excluding acquisition



#### On-site

Growth restrained by the end of a contract in Australia in 2015 and an insolvency of a customer in UK in 2015, +1.7% excluding these effects



#### Bulk

Highest growth contribution from Asia









#### Cylinder

Development supported by Specialty Gases in Americas

# Gases Division | Operating segments

## Solid comparable growth in Asia




Reported growth
  Comparable growth: excluding currency and natural gas price effects
  Operating profit margin


# Engineering Division | Key figures

## Solid margin in a challenging environment

### Revenue [EUR m]




### Operating profit [EUR m]




■ Reported growth    □ Operating profit margin

### Order intake [EUR m]



### Order backlog [EUR m]




- Order intake in Q1 remains affected by postponement of investment decisions in particular in the petrochemical industry
- Revenue development in line with progress of projects
- Order backlog remains on a solid level




# Financial Performance | Key figures

## Strong operating cash flow development

### Cash flow



### Net debt / operating profit



- Net debt decreased to EUR 7.2bn supported by strong operating cash flow
- 20 April 2016: 12 year EUR 750m senior bond issue with record-low coupon of 1%
- Ratings unchanged A+ /A-1 (S&P) and A2/P-1 (Moody's) with stable outlook

\*Before pension funding of EUR 300m

## 1. Operational Performance

## 2. Strategic Focus

- Resilient Gases Business Model
- Growth
- Returns

## 3. Outlook

## Appendix

# Strategic focus

Built on strong Integrated Gases & Engineering foundation



THE LINDE GROUP

## Growth

## Resilient Gases Business Model

## Returns

- Diversified opportunities in a global footprint
- Increasing gases intensity
- Innovations & applications
- Healthcare


- Strong competitive positions
- Highly diversified industry and customer portfolio

- HPO and restructuring
- Leveraging the existing asset base

Integrated Gases &  
Engineering Model

# Well positioned | Integrated Gases & Engineering model

## Synergies built on strong Engineering foundation




# Strategic focus | Resilient Gases Business Model

## Strong competitive positions

### Leading in local markets

- Number 1 or 2 in more than 70 countries
- 90 percent of Gases revenue is generated in 30 countries
- Majority of Merchant revenue generated in geographies with strong market positions


### Revenue split by Merchant market share



# Strategic focus | Resilient Gases Business Model

## Highly diversified customer base with contracted business


### Revenue split of product areas by industry



Primary industries

Secondary industries

### Revenue split by industry



#### Healthcare

- Hospital care, intermediate care, homecare
- Structural growth from growing and ageing population



#### On-site

- 15-year take-or-pay contracts with base facility fees
- Indexation and pass-through of energy and feedstock costs
- Strong customer portfolio



#### Bulk

- Multi-year contracts
- Tank rentals
- Driven by application know-how




#### Cylinder


- Includes Specialty Gases
- Cylinder rentals
- Driven by application know-how

# Strategic focus | Growth


## Linde in EMEA



### Revenue split by product area



### Revenue split by industry



- Established clusters in Northern Europe, Continental Europe and the UK
- Growing presence in Middle East & Eastern Europe and longstanding leading position in Africa


Source: Linde data for the year 2015, market ranking for industrial gases and respiratory healthcare (excl. equipment)

# Strategic focus | Growth

## Linde in EMEA



### IP development forecast for EMEA




Source: Oxford Economics, January 2016

### Growth drivers



#### On-site

Development of Chemistry & Energy sector in Middle East and Eastern Europe continues to create additional opportunities



#### Bulk & Cylinder

Food & Beverages and Manufacturing customers seeking for application and service offerings that boost their productivity and increase their differentiation



#### Healthcare

Ageing population and increasing chronic diseases drive demand for cost-effective treatments both in hospitals and at home


### Key differentiators

- Strong position and established presence in all major markets with high asset and customer density
- Ability to capture attractive On-site opportunities based on synergies enabled by Linde Engineering
- Combination of deep technical and application competencies with complete product and service offerings
- Strong competitive position based on sizable global homecare presence and extensive experience in healthcare




# Strategic focus | Growth


## Linde in Asia/Pacific



### Revenue split by product area



### Revenue split by industry



- Strong position in major industrial clusters in Asia/Pacific
- Solid track record of revenue growth built on a diverse portfolio of leading customers


Source: Linde data for the year 2015, market ranking for industrial gases and respiratory healthcare (excl. equipment)

# Strategic focus | Growth

## Linde in Asia/Pacific



### IP development forecast for APAC




Source: Oxford Economics, January 2016

### Growth drivers



#### On-site

Higher gas intensity levels to improve productivity, save fuel and increase product value



#### Bulk & Cylinder

Growing customer interest in Asian markets for more advanced applications (i.e. welding conversion) as well as higher value gas consumption in Electronics



#### Healthcare


Ageing and increasingly wealthy population with rising demand for healthcare services

### Key differentiators


- Established power zones in the East and South of China, India, Southeast Asia and Australia
- On-site supplier to leading local and international companies
- Locally based applications development and sales force to drive sales of higher value applications
- Growing Healthcare business that is well positioned to take advantage of long-term demographic trends

# Strategic focus | Growth


## Linde in the Americas



### Revenue split by product area



### Revenue split by industry



- Established footprint in major industrial clusters in North and South America
- Leader in US respiratory Homecare market

Source: Linde data for the year 2015, market ranking for industrial gases and respiratory healthcare (excl. equipment)


\*#4 in North America excl. Homecare

# Strategic focus | Growth

## Linde in the Americas



### IP development forecast for Americas Growth drivers




Source: Oxford Economics, January 2016



#### On-site

Further buildout of chemical industry and more stringent environmental regulations requiring cleaner fuels



#### Bulk & Cylinder

Use of higher quality gases in Manufacturing for new materials (i.e. aluminum, carbon fibre) and Electronics sectors



#### Healthcare

Continued rise in senior population and increasing diagnosis of chronic respiratory disease to drive increasing demand for Homecare

### Key differentiators


- Established footprint in major industrial clusters
- On-site supplier to major players in Chemistry & Energy, Metallurgy & Glass as well as Electronics
- Reliable partner in CO2 and Specialty Gases markets in North America with broad distribution network and supply base
- Leading player in US Homecare market with significant economies of scale and scope

# Strategic focus | Growth

## Established strong position in high growth regions

### Global market for industrial & medical gases

Annual consumption per capita in EUR: ■ Low: <10 ■ Medium: 10-30 ■ High: >30




Linde's position in regional markets

Countries without Linde presence

### Examples of countries with low, medium and high annual consumption per capita [EUR]


#### Example Low: China



#### Example Medium: Poland



#### Example High: United States



■ On-site ■ Bulk & Cylinder ■ Healthcare


Source: Linde data for 2015, figures for industrial gases and respiratory healthcare (excluding Electronics and equipment)

\*#4 in North America excl. Homecare


# Strategic focus | Growth

## Solid project pipeline balanced across geographies


Total capex of committed projects  
by on-stream date\*



Committed projects  
by region\*



EUR 3.1 bn market opportunities  
(18 months forward)



\* Projects > 10 m Euros

- Almost 50 percent of project investments in EMEA
- Gases capex/sales ratio in 2016 again expected to be lower compared to the previous years

- Market opportunities slightly lower compared to March 2015
- Decaptivation projects represent additional growth opportunities


■ New projects since 2015 ■ Projects already announced

■ EMEA ■ Asia/Pacific ■ Americas

# Strategic focus | Growth

Applications play an increasing role in Merchant business

## Share of Merchant revenue driven by tailored applications and solutions



## Broad portfolio of applications in various industries



### Examples in Bulk

- 1 CRYOCLEAN™
- 2 LoTOx™
- 3 OXYMIX™
- 4 SOLVOX™ OxyStream
- 5 REBOX™

### Examples in Cylinder

- 6 LINDOFLAMM®
- 7 VARIGON
- 8 ECOCYL™
- 9 MAPAX™

## Advantages of application and solutions approach

- Providing customer solutions creates higher value than pure molecule supply
- Even higher customer loyalty
- Transferability of solutions and know-how across industries and geographies

- |                          |                                                  |                      |                   |                             |
|--------------------------|--------------------------------------------------|----------------------|-------------------|-----------------------------|
| 1 Surface Cleaning       | 3 Efficiency improvement in chemistry & refining | 5 Reheating of steel | 6 Thermal heating | 8 Specialty gases packaging |
| 2 NOx emission reduction | 4 Low-energy oxygenation (aquaculture)           |                      | 7 Arc welding     | 9 Leak detection            |

# Strategic focus | Growth

Healthcare benefiting from global profile and innovations



THE LINDE GROUP

## Growth drivers

- Growing & ageing population
- Increasing number of patients with chronic respiratory diseases
- Increasing wealth in emerging markets
  - Trend towards digitalisation esp. focusing on efficiency and patient safety

## Innovative services in Hospital care



- Digital packaging (LIV-IQ) supports higher efficiency, automation and real-time availability of patient information
- Pilots for centralised cylinder management (e.g. automatic replenishment) links customers to Linde supply chain



## Strong global business footprint in Homecare



- Broad offering for respiratory homecare
- Shift from hospital to intermediate & homecare
- Increasing density through consolidation

Oxygen  
therapy

Specialty  
services

Sleep  
apnea

Infusion/  
enteral

## Linde's market position

- Global presence in 60 countries: Serving more than 1.7 million homecare patients and supplying ~20,000 hospitals
- Cost leadership through economies of scale (e.g. purchasing power)
- Know-how transfer between markets (e.g. distribution network, best practices)





# Strategic focus | Returns


Generating savings through efficiency and cost management



THE LINDE GROUP


## Learning Organisation

### Gross cost savings



## Additional improvement measures & expected savings

- **Australia**  
to adjust to deindustrialisation
- **South Africa and South America**  
to adapt to a challenging macro-economic environment
- **Total EUR 258m cost incurred**  
in 2014 and 2015



Rigid cost management in Mature Markets and in Healthcare

# Strategic focus | Returns

## Leveraging the existing asset base

### On-site



- Increase specific gas consumption via additional applications
- Pipeline extensions (micro-cluster development)
- Customer ramp-up of plants

### Bulk



- Increase specific gas consumption via additional applications
- Acquisition of new customers within existing clusters

### Cylinder



- Increase specific gas consumption via additional applications
- Ongoing optimisation through redeployment of mobile assets between regions

Relevant measures to improve returns

Impact

- Increased contribution from existing asset base

- Room to grow in most geographies without further investment being required

- Better utilisation of existing mobile assets

# Strategic focus | Returns

Dividend increase of 9.5 percent to EUR 3.45




THE LINDE GROUP

## Dividend development

[EUR per share]

Dividend CAGR 9.7%



Payout ratio\*

42.0%

51.0%

37.3%

36.5%

40.6%

42.3%

44.2%

49.9%

\*Based on EPS before non-recurring items

# Agenda



## 1. Operational Performance

## 2. Strategic Focus

- Resilient Gases Business Model
- Growth
- Returns

## 3. Outlook

## Appendix


# Outlook | Capex

## Capex / sales ratios reduced


### Group capex/sales ratio

10.1%    10.1%    9.9%    12.9%    13.6%    11.5%    10.8%

### Gases capex/sales ratio



### Gases capex [EUR m]



## Short-term outlook\*

◆ 2016

2015 adjusted for FX

### Group

Revenue	-3 to +4% versus 2015 adjusted for FX	17.256 billion Euros
Operating profit	-3 to +4% versus 2015 adjusted for FX	3.970 billion Euros
ROCE	Around 9 percent	Potentially impacted

### Gases Division

Revenue	±0 to +5% versus 2015 adjusted for FX	14.558 billion Euros
Operating profit	-1 to +6% versus 2015 adjusted for FX	3.997 billion Euros

### Engineering Division

Revenue	2.0 to 2.4 billion Euros
Operating margin	Around 8 percent

## Medium-term outlook\*\*

◆ 2017

### Group

Operating Profit	4.2 to 4.5 billion Euros
ROCE	9 to 10 percent

Please see definitions of key financial figures in the appendix

\*Dependent on economic development | 2015 adjusted for FX based on forward exchange rates from end of March 2016

\*\*Dependent on economic development and based on forward exchange rates from time of communication in November 2015

# Group | Use of cash flow

Balancing returns & future growth based on a solid financial position



THE LINDE GROUP

## Invest for profitable growth

Gases capex/sales ratio of 11-12%  
for 2016 (12.4% in 2015) below  
mid-term average of ~13%



## Dividend approach

Dividend increased  
to EUR 3.45



## Solid capital structure

Net debt declined to  
EUR 7.2bn resulting in a net  
debt/ EBITDA ratio of 1.7x



## 1. Operational Performance



## 2. Strategic Focus

- Resilient Gases Business Model
- Growth
- Returns

## 3. Outlook





# Group | Potential currency impact on 2016 outlook



	USD	TWD	INR	MYR	COP	RUB	CAD	ARS	BRL	CNY	AUD	GBP	ZAR
Average rate in 2015	1.11	35.25	71.17	4.34	3,047.3	68.01	1.42	10.27	3.70	6.98	1.48	0.73	14.17
Applied forward rate*	1.13	36.81	77.15	4.51	3,546.6	78.27	1.49	16.40	4.30	7.42	1.51	0.79	17.46

\*Based on forward exchange rates from end of March 2016

# Gases Division | Potential currency impact on 2016 outlook



	USD	TWD	INR	MYR	COP	RUB	CAD	ARS	BRL	CNY	AUD	GBP	ZAR
Average rate in 2015	1.11	35.25	71.17	4.34	3,047.3	68.01	1.42	10.27	3.70	6.98	1.48	0.73	14.17
Applied forward rate*	1.13	36.81	77.15	4.51	3,546.6	78.27	1.49	16.40	4.30	7.42	1.51	0.79	17.46

\*Based on forward exchange rates from end of March 2016


## Group | Currency impact

Impact on revenue and operating profit in Q1 2016




THE LINDE GROUP

### Impact on Group revenue in 2016



### Impact on Group operating profit in 2016



# Group | Financial position

## Liquidity position remains strong




### EUR 2.5bn committed revolving credit facility

- Refinancing in 2013 with diversified group of 33 domestic and international banks
- Final maturity in 2020 after exercising two extension options in 2014 and 2015
- No financial covenants
- Fully undrawn

### Central liquidity position

- Strong liquidity profile remains centerpiece in financial strategy
- Supported by continuous efforts to upstream cash
- Very conservative investment guidelines


[EUR m]




# Group | Financial position

## Conservative financing strategy

### Gross financial debt by instrument



### Capital market debt by maturity [EUR m]




### Maturity profile remains very long-dated

- Approx. 90% of total financial debt is due beyond 2016
- Approx. 35% of total financial debt has a longer maturity than 5 years
- Excellent access to capital markets: long-term financing across markets and currencies
- 20 April 2016: 12 year EUR 750m senior bond issue with record-low coupon of 1%

# Group | Pensions

## Key figures 2015

### Pension plan assets portfolio structure



Status: 31/12/2014 and 31/12/2015

### Net obligation [EUR m]

	DBO	Plan assets	Net obligations
01/01/2015	7,144	6,068	1,076*
Service costs	86	-	86
Net financing	230	206	24
Actuarial losses/gains	- 308	- 196	- 112
Contributions/payments	- 566	- 401	- 165
Other	292	263	29
31/12/2015	6,878	5,940	938*

\* Figure does not include provisions for similar obligations

# Group | Q1 2016

## Key P&L items



[EUR m]	Q1 2015	Q1 2016	Δ in %
Revenue	4,398	4,262	-3.1
Operating profit	1,010	991	-1.9
Operating margin	23.0	23.3	+30bps
PPA depreciation for BOC	-63	-46	+27.0
Depreciation & amortisation (excl. PPA BOC)	-404	-415	-2.7
Other non-recurring items (expenses for restructuring)	-20	-	-
EBIT	523	530	+1.3
Financial result	-98	-89	+9.2
Taxes	-101	-108	-6.9
Profit for the year – attributable to Linde AG shareholders	300	306	+2.0
EPS reported [EUR]	1.62	1.65	+1.9

# Group | Q1 2016

## Cash flow statement


[EUR m]	Q1 2015	Q1 2016
Operating profit	1,010	991
Change in working capital	-161	24
Income taxes paid	-99	-36
Other changes	-10	-96
<b>Operating cash flow</b>	<b>740</b>	<b>883</b>
Investments in tangibles/intangibles	-442	-405
Payments for acquisitions	-71	-180
Other (incl. financial investments)	37	39
<b>Investment cash flow*</b>	<b>-476</b>	<b>-546</b>
<b>Free cash flow before financing</b>	<b>264</b>	<b>337</b>
Interest and swaps, dividends	-52	-48
Other changes	-6	-8
<b>Change in cash and financial debt</b>	<b>206</b>	<b>281</b>

\*Excluding investments in / disposals of securities; Q1 2015: EUR -51m; Q1 2016: EUR -109m



# Gases Division | Integrated Gases Model

## Highest value/molecule ratio in Cylinder




Based on FY 2015 revenues

# Gases Division | Integrated Gases Model

## Leading position in all product areas

2015 Gases revenue: EUR 15.2bn


### Healthcare – Global #1



- Hospitals & Homecare
- Bulk & Cylinder gases
- Structural growth from growing and ageing population




### On-site – Global #2



- 15 year take-or-pay contracts with base facility fees
- Indexation and pass-through of energy and feedstock costs




### Bulk – Global #1



- Driven by Linde's leading application know-how
- Multi-year contracts
- Tank rentals



### Cylinder – Global #1




- Driven by Linde's leading application know-how
- Includes Specialty Gases
- Cylinder rentals




# Gases Division | Example Greater China

## Country customer portfolio


### Others & Healthcare




### Metallurgy & Glass



### Electronics



### Chemistry & Energy



# Gases Division | Cluster


## Integrated offering – example Ningbo

China



### Fully integrated cluster

- 5 ASUs and 2 HyCo plants linked by ~140 km pipeline network
- Production of GOX, GAN, GHY, LOX, LIN and LAR
- Total ASU capacity: 141,000 Nm<sup>3</sup>/h
- HyCo capacity: 3,200 Nm<sup>3</sup>/h
- Several filling stations within the cluster
- On-site, Bulk and Cylinder customers
- Supplying different industries within the cluster, e.g. steel, chemicals, electronics




# Gases Division | Lincare


## Industry leader with balanced business & payor mix




### Leading Industry Position



### Business Mix



### Payor Mix



Source: Linde data

\* Pro forma | Lincare's acquisition of American Homepatient successfully closed on 1 February 2016


# Gases Division | Lincare

## Key growth drivers

### Demographics

- Baby boom generation entering retirement
- Men and women age 65 today can expect to live, on average, until age 84.3 and 86.6, respectively

### Expected U.S. population age 65 and over




Sources: U.S. Census Bureau, Social Security Administration

### Increasing COPD Population

- Only one-third of those with COPD are diagnosed\*
- As knowledge and awareness grow, expect increase in diagnosis and treatment

### Percent of U.S. population diagnosed with COPD



Sources: Linde, \*American Lung Association

# Strategic focus | Growth

## Expanding product-service-offerings in Food & Beverage

### Industry trends

- Increased consumption of processed food
- Rising demand for healthy and fresh food
- Industry consolidation
- Declining supplies of wild-captured seafood

### Demand drivers for gases

- Larger capacity production lines
- Improving the cold chain
- Demand for longer shelf life
- Specially designed food freezers
- Higher demand for seafood from aquaculture

## Food Freezing

### CRYOLINE Range



- Established range of hardware
- Best in-class proprietary technology with high market acceptance

### Innovation: CRYOLINE PE



- Cryoline PE latest innovation to rapidly cool soups and sauces
- 80% increase in capacity & 35% efficiency improvement

## Aquaculture

### SOLVOX



- SOLVOX proprietary application
- Position as market leader in Norway and Linde's aquaculture innovation center are key success factors

### Innovation: SOLVOX Drop-In




- Drop-In unit with exceptional initial market feedback
- ~20-30% cost saving in sea lice treatment
- Value-adding in continuous oxygenation

# Gases Division | Revenue bridge

Price/volume increase of 2.9 percent

[EUR m]



\*Including EUR 47m changes in consolidation from American HomePatient acquisition



# Gases Division | Quarterly data

## Reporting segments

EMEA [EUR m]	Q1 2015	Q1 2016
Revenue	1,472	1,410
Operating profit	441	430
Operating margin	30.0%	30.5%


Asia/Pacific [EUR m]	Q1 2015	Q1 2016
Revenue	994	969
Operating profit	252	254
Operating margin	25.4%	26.2%

Americas [EUR m]	Q1 2015	Q1 2016
Revenue	1,252	1,252
Operating profit	315	322
Operating margin	25.2%	25.1%

# Gases Division | Capex split

Capex/sales ratio in 2015 of 12.4 percent

## Capex split by operating segments [EUR m]



- Decrease in capex/sales ratio in all operating segments
- Decrease in investment activities in EMEA mainly driven by Middle East and Eastern Europe balanced by additional new On-site approvals in Central Europe
- Increase of capex in North America affected by currency effects




# Gases Division | Revenue split by Regional Business Unit

EMEA [EUR m]	2015
Central Europe	1,709
Northern Europe	794
Southern Europe	883
Africa & UK	1,663
Middle East & Eastern Europe	1,028

Asia/Pacific [EUR m]	2015
East Asia	1,845
South Asia & ASEAN	988
South Pacific	1,329

Americas [EUR m]	2015
North & South America	5,183



EMEA
  Asia/Pacific
  Americas
  Countries without Linde presence

# Engineering Division

135 years of experience | A broad range of technologies



THE LINDE GROUP


## Internal use & sales to external parties

### Air separation plants

for production of oxygen, nitrogen, argon & rare gases

### Hydrogen & synthesis gas plants

for production of hydrogen, carbon monoxide, ammonia & methanol



## Sales to external parties

### Natural gas plants

for purification, fractionation & conditioning of gas mixtures, recovery, liquefaction & storage of natural gas

### Petrochemical plants


for production & recovery of olefins, acetylene, butadiene, aromatics, poly- & alpha-olefins, polyethylene & polypropylene

- More than 7,000 employees
- Provides in-depth application know-how
- Leveraging existing customer relationships
- Provides cost & energy efficient plants
- 1,000 process engineering patents
- 4,000 completed plant projects
- 6 Linde Engineering hubs globally


# Engineering Division | Order intake & backlog

## Largest share of order intake from EMEA

Order intake by plant type




Order backlog by plant type



- Air Separation Plants
- Hydrogen/Synthesis Gas Plants
- Olefin Plants
- Natural Gas Plants
- Others

Order intake by region



# Group | BOC PPA


## Expected depreciation & amortisation

- Development of depreciation and amortisation
- Impact in 2015: EUR 228m
- Expected range adjusted due to exchange rate effects

### Expected range [EUR m]

2016	180 - 200
2017	165 - 185
...	
2022	< 120

### BOC PPA Depreciation Planning [EUR m]



Operating Profit	Earnings per Share (EPS) before non-recurring items	Earnings per Share (EPS) (reported)	Return on Capital Employed (ROCE)
Return	Return	Return	Return
EBIT before non-recurring items adjusted for amortisation of intangible assets and depreciation of tangible assets	Profit for the period before non-recurring items attributable to Linde AG shareholders	Profit for the period attributable to Linde AG shareholders	EBIT before non-recurring items
	Shares	Shares	Average Capital Employed
	Number of weighted average outstanding shares	Number of weighted average outstanding shares	Equity (incl. non-controlling interests) + financial debt + liabilities from finance leases + net pension obligations - cash, cash equivalents and securities - receivables from finance leases

## Dow Jones Sustainability Index

Linde listed among leading companies (top 10%) in chemicals industry

## MSCI Global Sustainability Indexes

Linde confirmed as a constituent of the MSCI Global Sustainability Indexes

## FTSE4Good

Linde is a component of the FTSE4Good Index series

## STOXX Global ESG Leaders Indices


Linde represented in the EURO STOXX Sustainability Top 40 and the STOXX Global ESG Leaders indices

## CDP

Linde admitted to the regional Carbon Disclosure Leadership Index for Germany, Austria and Switzerland



## Financial calendar



### Contact

**Phone:**

+49 89 357 57 1321

**Email:**

[investorrelations@linde.com](mailto:investorrelations@linde.com)

**Internet:**

[www.linde.com](http://www.linde.com)

### Linde share information

**Type of share:**

Bearer shares

**Stock exchanges:**

All German stock exchanges

**Security reference number:**

ISIN DE0006483001

CUSIP 648300

### Linde ADR information

**Ticker Symbol:**

LNEG

**DR ISIN:**

US5352230204

**Depository Bank:**

Deutsche Bank

**Structure:**

ADR Level I, Sponsored



The Linde IR app is  
now available at:

